Business Description
Eiger BioPharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US28249U1051
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | -0.37 | |||||
Debt-to-Equity | -2.85 | |||||
Debt-to-EBITDA | -0.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -24.41 | |||||
Beneish M-Score | -3.25 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 9.8 | |||||
3-Year FCF Growth Rate | 9.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.36 | |||||
9-Day RSI | 66.22 | |||||
14-Day RSI | 55.88 | |||||
6-1 Month Momentum % | -35.74 | |||||
12-1 Month Momentum % | -81.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.48 | |||||
Days Inventory | 36347.92 | |||||
Days Sales Outstanding | 57.19 | |||||
Days Payable | 99620.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.4 | |||||
Shareholder Yield % | -81.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 99.85 | |||||
Operating Margin % | -455.12 | |||||
Net Margin % | -475.26 | |||||
FCF Margin % | -474.11 | |||||
ROE % | -417.47 | |||||
ROA % | -97.05 | |||||
ROIC % | -439.77 | |||||
ROC (Joel Greenblatt) % | -6501.78 | |||||
ROCE % | -138.67 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.3 | |||||
EV-to-EBIT | -0.31 | |||||
EV-to-EBITDA | -0.31 | |||||
EV-to-Revenue | 1.35 | |||||
EV-to-FCF | -0.26 | |||||
Earnings Yield (Greenblatt) % | -322.58 | |||||
FCF Yield % | -1553.75 |